Higher serum CCL17 may be a promising predictor of acute exacerbations in chronic hypersensitivity pneumonitis

Respiratory Research

Table 1 Patient demographics at baseline†

Characteristics	AE group (n = 14)	NAE group (n = 42)	p value
Gender			0.350
Female	10	22
Male	4	20
Age, yr	65 (53–75)	64 (34–81)	0.557
Smoking			0.089
Never	4	23
Ever	10	19
VC,% predicted	68.6 (38.7-114.0)	80.7 (37.6-130.9)	0.279
PaO₂, mm Hg	78.0 (49.8-94.1)	79.0 (47.6-98.0)	0.547
A-aDO₂, mm Hg	18.1 (2.4-46.4)	17.4 (9.7-56.8)	0.622
KL-6, U/ml	1500 (867–5450)	1430 (319–8920)	0.737
SP-D, ng/ml	436.5(136–536)	236.5(49–934)	0.101
Fibrosis score	2.4 (0.8-2.9)	1.8 (0.0-3.8)	0.426
Ground-glass score	2.0 (0.6-4.0)	2.2 (1.2-4.8)	0.110
Histologic pattern			0.024*
UIP	12	19
fNSIP	2	14
cNSIP	0	9
Treatment			0.020*
No treatment	0	9
CS	4	19
CS + I	10	10
N/A	0	4
Follow-up (months)	27.5 (5–128)	53.0 (2–162)	0.055

Definitions of abbreviation: AE acute exacerbations of chronic HP, NAE non-exacerbations of chronic HP, VC vital capacity, PaO₂ partial pressure of carbon dioxide in arterial blood, A-aDO₂ alveolar-arterial oxygen difference, KL-6 Krebs on den Lungen-6, SP-D surfactant protein-D, UIP usual interstitial pneumonia, fNSIP fibrotic nonspecific interstitial pneumonia, cNSIP cellular nonspecific interstitial pneumonia, CS corticosteroid only, I immunosuppressant, N/A not available.
†Data are given as the median (range; minimum data-maximum data) or numbers.
*: p < 0.05.

ISSN: 1465-993X